All DcR2 reagents are produced in house and quality controlled, including 13 DcR2 Antibody, 1 DcR2 ELISA, 24 DcR2 Gene, 1 DcR2 IPKit, 4 DcR2 Lysate, 4 DcR2 Protein, 1 DcR2 qPCR. All DcR2 reagents are ready to use.
Recombinant DcR2 proteins are expressed by HEK293 Cells with fusion tags as C-human IgG1-Fc, C-His, C-human IgG1-Fc & His.
DcR2antibodies are validated with different applications, which are ELISA, ELISA(Cap), WB, IHC-P, IP, ELISA(Det).
DcR2cDNA clones are full length sequence confirmed and expression validated. There are 13 kinds of tags for each DcR2 of different species, especially GFP tag, OFP tag, FLAG tag and so on. There are three kinds of vectors for choice, cloning vector, expression vector and lentivrial expression vector.
DcR2ELISA Kit are quality controlled by 8 internation QC standard which guarantee every ELISA Kit with high quality.
Tumor necrosis factor receptor superfamily member 10D (TNFRSF10D), also known as TNF-related apoptosis-inducing ligand receptor 4 (TRAIL R4), CD264, and Decoy receptor 2, is a member of the TNF-receptor superfamily. This receptor contains an extracellular TRAIL-binding domain, a transmembrane domain, and a truncated cytoplamic death domain. This receptor does not induce apoptosis, and has been shown to play an inhibitory role in TRAIL-induced cell apoptosis. TRAIL R4/CD264/TNFRSF10D is widely expressed, in particular in fetal kidney, lung and liver, and in adult testis and liver. TRAIL R4/CD264/TNFRSF10D is also expressed in peripheral blood leukocytes, colon and small intestine, ovary, prostate, thymus, spleen, pancreas, kidney, lung, placenta and heart. The signaling capacity of TRAIL R4 is similar to that of TRAIL R1 and TRAIL R2 with respect to NF-κB activation, but differs in its inability to induce apoptosis. TRAIL R4 retains a C-terminal element containing one third of a consensus death domain motif. Transient overexpression of TRAIL R4 in cells normally sensitive to TRAIL-mediated killing confers complete protection, suggesting that one function of TRAIL R4 may be inhibition of TRAIL cytotoxicity.